Last June, New York State Attorney General Eliot Spitzer sued the maker of an antidepressant for withholding unfavorable information about the safety and effectiveness of a drug. The suit, filed in the New York Supreme Court and settled this summer, claimed that GlaxoSmithKline conducted at least five studies on the...

Guidelines are what Peter Sims seeks to provide in "Little Bets," an enthusiastic, example-rich argument for innovating in a particular way—by deliberately experimenting and taking small exploratory steps in novel directions. Some little bets will not pay off, of course, in which case little is lost; but others may pay off in big ways.

What does it take to get the FDA to revisit a precedent?

Do such commonly prescribed antidepressants as Celexa, Paxil, and Zoloft cause suicide in children?

How will new prescription label requirements affect pharmaceutical companies?

A new Food and Drug Administration labeling rule could provide better information to consumers and prevent hyperactive litigation.

A steady stream of dire announcements will eventually fatigue the public for important warnings and devalue the voice through which the agency speaks.

The Food and Drug Administration should not allow sensationalism in the media to unduly influence its treatment of SSRIs and anti-depressant drugs.